Edition:
United States

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

245.20CHF
19 Oct 2018
Change (% chg)

CHF5.80 (+2.42%)
Prev Close
CHF239.40
Open
CHF239.80
Day's High
CHF246.20
Day's Low
CHF239.00
Volume
44,643
Avg. Vol
27,580
52-wk High
CHF255.00
52-wk Low
CHF209.40

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.99
Market Cap(Mil.): CHF210,924.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.30
Yield (%): 3.40

Financials

  RO.S Industry Sector
P/E (TTM): 20.06 29.75 32.14
EPS (TTM): 12.18 -- --
ROI: 21.29 13.18 12.83
ROE: 41.72 15.14 14.95

BRIEF-Roche CEO Says 'Confidence Rising' in Sales Growth in 2019, Beyond

* CEO SAYS HIS CONFIDENCE RISING QUARTER-BY-QUARTER THAT DRUGMAKER WILL CONTINUE SALES GROWTH IN 2019, BASED ON TRIAL RESULTS; "WE ARE SURE WE CAN OUTGROW THE IMPACT OF BIOSIMILARS"

Oct 17 2018

BRIEF-Roche CEO Says Confident In Ability To Sustain Growth Beyond 2018

* SHARES SEEN RISING 1.9 PERCENT AFTER Q3 RESULTS - PREMARKET INDICATORS

Oct 17 2018

BRIEF-Roche Launches Tumor Tissue Analysis Kits For Oncology Research

* ROCHE LAUNCHES NGS AVENIO TUMOR TISSUE ANALYSIS KITS FOR ONCOLOGY RESEARCH

Oct 15 2018

CORRECTED-UPDATE 1-U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug

Oct 10 Celltrion Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan, on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration.

Oct 10 2018

CORRECTED-U.S. FDA panel backs Celltrion copycat drug of Roche blood cancer drug

Oct 10 An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously in favor of Celltrion Inc's copycat drug of Roche Holding AG's blood cancer drug Rituxan.

Oct 10 2018

U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug

Celltrion Pharm Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan, on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration.

Oct 10 2018

U.S. FDA panel backs Celltrion copycat drug of Roche blood cancer drug

Oct 10 An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously in favor of Celltrion Pharm Inc's copycat drug of Roche Holding AG's blood cancer drug Rituxan.

Oct 10 2018

BRIEF-Roche Updates Data On Ocrevus To Treat Multiple Sclerosis

* OCREVUS (OCRELIZUMAB) DATA SHOW EARLY INITIATION OF TREATMENT REDUCES DISABILITY PROGRESSION OVER FIVE YEARS IN RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS Source text for Eikon: Further company coverage:

Oct 10 2018

BRIEF-Roche To Present New Data From Cancer Immunotherapy Programme at ESMO

* ROCHE TO PRESENT NEW POSITIVE DATA FROM ITS BROAD CANCER IMMUNOTHERAPY PROGRAMME

Oct 09 2018

BRIEF-Go Therapeutics Enters Into Agreement With Roche For Glycotargeting Bispecific Cancer Treatment

* GO THERAPEUTICS ENTERS INTO A LICENSE AGREEMENT WITH ROCHE FOR NEW GLYCOTARGETING BISPECIFIC CANCER TREATMENT

Oct 02 2018

Earnings vs. Estimates